Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-70. (Cancel)

71. (Currently amended and withdrawn) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of any one of Claims **58** ~~**and 59**~~ **118 and 119**.

72-117 (Cancel)

118. (New) A compound having a formula



and their pharmaceutically acceptable salts, wherein

P^2 is selected from the group consisting of —C(O)—, —CH(OH)—, —C(O)O—, —OC(O)—, —NHC(O)NH—, —OC(O)NH—, —NHC(O)O—, —C(O)NH—, —NHC(O)—, and $O(CH_2CH_2O)_q$;

P^3 is selected from the group consisting of C_2-C_6 alkynyl, C_1-C_6 haloalkyl, aryl, heteroaryl, $-NHS(O)_2R^2$, $—C(O)OR^2$ and carboxylic acid analogs, wherein R^2 is a member selected from the group consisting of hydrogen, unsubstituted C_1-C_4 alkyl, substituted C_1-C_4 alkyl, unsubstituted C_3-C_8 cycloalkyl, substituted C_3-C_8 cycloalkyl, unsubstituted aryl, substituted aryl, unsubstituted aryl C_1-C_4 alkyl, and substituted aryl C_1-C_4 alkyl;

the subscript q is 0 to 3;

L^1 is unsubstituted C_2-C_6 alkylene or substituted C_2-C_6 alkylene;

L^2 is unsubstituted C_2-C_{12} alkylene or substituted C_2-C_{12} alkylene.

119. (New) A compound having a formula (I):



(I)

and their pharmaceutically acceptable salts, wherein

R^1 is a member selected from the group consisting of aryl and heteroaryl;

P^1 is a primary pharmacophore selected from the group consisting of —NHC(O)NH—, -OC(O)NH—, —NHC(O)O—, —CH_2C(O)NH—, —C(O)NH— and —NHC(O)—;

P^2 is a secondary pharmacophore selected from the group consisting of —C(O)—, —CH(OH)—, —$O(CH_2CH_2O)_q$—, —C(O)O—, —OC(O)—, —NHC(O)NH—, —OC(O)NH—, -NHC(O)O—, —C(O)NH— and —NHC(O)—;

P^3 is a tertiary pharmacophore selected from the group consisting of C_2-C_6 alkynyl, C_1-C_6 haloalkyl, aryl, heteroaryl, —C(O)NHR^1, —C(O)NHS$(O)_2R^1$, —NHS$(O)_2R^2$, -C(O)OR^2 and carboxylic acid analogs, wherein R^2 is a member selected from the group consisting of hydrogen, unsubstituted C_1-C_4 alkyl, substituted C_1-C_4 alkyl, unsubstituted C_3-C_8 cycloalkyl, substituted C_3-C_8 cycloalkyl, unsubstituted aryl, substituted aryl, unsubstituted aryl C_1-C_4 alkyl, and substituted aryl C_1-C_4 alkyl;

the subscripts n and m are each independently 0 or 1, and at least one of n or m is 1, and the subscript q is 0 to 3;

L^1 is a first linker selected from the group consisting of unsubstituted C_2-C_6 alkylene, substituted C_2-C_6 alkylene, unsubstituted C_3-C_6 cycloalkylene, substituted C_3-C_6 cycloalkylene, unsubstituted arylene, substituted arylene, unsubstituted heteroarylene, and substituted heteroarylene; and

L^2 is a second linker selected from the group consisting of unsubstituted C_2-C_{12} alkylene, substituted C_2-C_{12} alkylene, unsubstituted arylene, substituted arylene, and combinations thereof.

120. (New) The compound according to any one of claims 118 and 119, wherein P^3 is –C(O)OR^2 or a carboxylic acid analog, wherein R^2 is selected from the group

consisting of hydrogen, unsubstituted C_1-C_4 alkyl, substituted C_1-C_4 alkyl, unsubstituted C_3-C_8 cycloalkyl, and substituted C_3-C_8 cycloalkyl.

121. (New) The compound according to any one of Claims 118 and 119, wherein P^3 is $-C(O)OR^2$ or a carboxylic acid analog, wherein R^2 is selected from the group consisting of hydrogen, methyl, and ethyl.

122. (New) The compound of Claim 119, wherein R^1 is selected from the group consisting of phenyl and naphthyl.

123. (New) The compound of Claim 119, wherein R^1 is phenyl.

124. (New) The compound Claim 119, wherein R^1 is phenyl, wherein the phenyl is either unsubstituted or substituted with from one to three substituents selected from the group consisting of halogen, lower alkyl, lower halo alkyl, lower alkoxy, C_3-C_5 cycloalkyl, and cyano.

125. (New) The compound of Claim 119, wherein P^1 is selected from the group consisting of –NHC(O)CH-, -OC(O)NH-, and –NHC(O)O-.

126. (New) The compound of Claim 119, wherein P^1 is -NHC(O)CH-.

127. (New) The compound of Claim 119, wherein L^1 is an alkylene of from 2 to 4 carbon atoms,

P^2 is not present; and

L^2 is an alkylene of from 2 to 8 carbon atoms.

128. (New) The compound of Claim 119, wherein P^1 is selected from the group consisting of —NHC(O)NH—, -OC(O)NH— and —NHC(O)O—;

n is 0;

m is 1;

L^1 is selected from the group consisting of unsubstituted C_2-C_6 alkylene, unsubstituted C_3-C_6cycloalkylene, substituted C_3-C_6cycloalkylene, unsubstituted arylene, and substituted arylene;

L^2 is selected from the group consisting of unsubstituted C_2-C_6 alkylene and substituted C_2-C_6 alkylene; and

P^3 is selected from the group consisting of C_2-C_6 alkynyl, C_1-C_6 haloalkyl, aryl, heteroaryl, —C(O)NHR^2, —C(O)NHS(O)$_2$R^2, —NHS(O)$_2$R^2, —C(O)OR^2, and carboxylic acid analogs, wherein R^2 is a member selected from the group consisting of hydrogen, unsubstituted C_1-C_4 alkyl, substituted C_1-C_4 alkyl, unsubstituted C_3-C_8 cycloalkyl, substituted C_3-C_8 cycloalkyl, unsubstituted aryl, substituted aryl, unsubstituted aryl C_1-C_4 alkyl, and substituted aryl C_1-C_4 alkyl.

129. (New) A compound having the formula selected from the group consisting of:



,



,



,



,

87  ,

88  ,

89  ,

90  ,

91  ,

92 

93 

94 

95 

96 

97 

98 

99 

100 

101 

102 

103 

104 

105 

,

106 
,

107 

,

108 

109 
,

110 
,

111  ,

112  ,

113  ,

114  ,

115  ,

116  ,

117  ,

118  ,

119 

120 

121 

122 

123 

124 

125 

126 

127 

128 

129 

130 

131 

132 

133 

134 

135 

136 

,

137 

,

138 

,

139 

,

140 

,

141 

,

142 

,

143 

,

144 

,

145  ,

146  ,

147  ,

148  ,

149  ,

150  ,

151  ,

152  ,

153 

154 

155 

156 

157 

158 

159 

160 wherein Z is O or NH;

161 R^3 is alkyl;

162 n1 is 1, 2, 3, 4, 6, 7, 9, 10, or 11;

163 n2 is 1, 2, 3, or 4;

164 n3 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

165 and their pharmaceutically acceptable salts.

166 **130.** (New) A compound having the formula:



131. (New) A compound having a formula



and their pharmaceutically acceptable salts, wherein

P^3 is selected from the group consisting of C_2-C_6 alkynyl, C_1-C_6 haloalkyl, aryl, heteroaryl, $-NHS(O)_2R^2$, $—C(O)OR^2$ and carboxylic acid analogs, wherein R^2 is a member selected from the group consisting of hydrogen, unsubstituted C_1-C_4 alkyl, substituted C_1-C_4 alkyl, unsubstituted C_3-C_8 cycloalkyl, substituted C_3-C_8 cycloalkyl, unsubstituted aryl, substituted aryl, unsubstituted aryl C_1-C_4 alkyl, and substituted aryl C_1-C_4 alkyl;

the subscript m is 1;

L^1 is unsubstituted C_3-C_4 alkylene or substituted C_3-C_4 alkylene;

L^2 is unsubstituted C_8 alkylene or substituted C_8 alkylene.

132. (New) A compound having the formula: